An Act relative to insulin access

This bill caps the out-of-pocket cost for insulin at $100 per 30-day supply for all patients, regardless of insulin type or prescription amount. It requires pharmaceutical companies with Medicaid rebate agreements to offer free 30-day insulin supplies to individuals urgently needing insulin (with less than 7 days' supply) who meet income criteria (≤400% of federal poverty level) and lack private drug coverage. Eligible individuals must provide proof of financial need and have a prescription. The cap applies to all insurers, manufacturers, and government programs covered under the bill, ensuring consistent cost limits without requiring additional coverage.